Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo-Reference-Cited by-同舟云学术

Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo

Published:2017-05 Issue: Volume:46 Page:112-123
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Sunay Melek M.E.,Foote Jeremy B.,Leatherman James M.,Edwards Justin P.,Armstrong Todd D.,Nirschl Christopher J.,Hicks Jessica,Emens Leisha A.

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference45 articles.

1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discov.,2013

2. The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas;Schuster;Blood,2011

3. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma;Parsa;Nat. Med.,2006

4. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors;Knight;J. Clin. Investig.,2013

5. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice;Machiels;Cancer Res.,2001

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment;Journal of the Formosan Medical Association;2024-02

2. Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma;Diagnostics;2023-04-18

3. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma;Frontiers in Immunology;2023-03-01

4. Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis;Acta Pharmacologica Sinica;2022-07-01

5. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy;OncoImmunology;2022-05-26